Literature DB >> 15003309

Negative regulation of gamma-globin gene expression by cyclic AMP-dependent pathway in erythroid cells.

Akio Inoue1, Yuichi Kuroyanagi, Kiminori Terui, Paolo Moi, Tohru Ikuta.   

Abstract

OBJECTIVE: Fetal hemoglobin inducers such as hemin, butyrate, and hydroxyurea stimulate gamma-globin gene expression by activating the cyclic GMP (cGMP)-dependent pathway. Although cGMP activates the cyclic AMP (cAMP)-dependent pathway by suppressing cGMP-inhibited phosphodiesterase 3 (PDE3), the effects of the cAMP-dependent pathway on gamma-globin gene expression are unknown.
MATERIALS AND METHODS: The cAMP-dependent pathway was activated in K562 cells using the adenylate cyclase activator forskolin. Expression of gamma-globin mRNA was examined by primer extension, and transcriptional activity of the gamma-globin gene promoter was determined by reporter gene assays.
RESULTS: PDE3 was expressed in K562 cells at a high level. The cAMP-dependent pathway was found to be activated in K562 cells in which the cGMP-dependent pathway was activated by hemin. Activation of the cAMP-dependent pathway by forskolin inhibited hemin-induced expression of gamma-globin mRNA and decreased transcriptional activity of the gamma-globin gene promoter. The levels of phosphorylation of mitogen-activated protein kinases (MAPKs) were not affected by the cAMP-dependent pathway.
CONCLUSIONS: These results suggested that the cAMP-dependent pathway, which is independent of MAPK pathways, plays a negative role in gamma-globin gene expression in K562 cells. cAMP and cGMP may have differential roles in the regulation of gamma-globin gene expression in erythroid cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003309     DOI: 10.1016/j.exphem.2003.12.006

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  12 in total

1.  The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease.

Authors:  Tohru Ikuta; Adekunle D Adekile; Diana R Gutsaeva; James B Parkerson; Shobha D Yerigenahally; Betsy Clair; Abdullah Kutlar; Nadine Odo; C Alvin Head
Journal:  Blood Cells Mol Dis       Date:  2011-09-25       Impact factor: 3.039

Review 2.  Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: Strategies to treat sickle cell disease.

Authors:  Betty S Pace; Li Liu; Biaoru Li; Levi H Makala
Journal:  Exp Biol Med (Maywood)       Date:  2015-08

Review 3.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

4.  Inhibition of erythroblast growth and fetal hemoglobin production by ribofuranose-substituted adenosine derivatives.

Authors:  Natarajan V Bhanu; Y Terry Lee; Patricia A Oneal; Nicole M Gantt; Wulin Aerbajinai; Pierre Noel; Craig J Thomas; Jeffery L Miller
Journal:  Biochim Biophys Acta       Date:  2008-06-30

5.  Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves gamma-globin activation by CREB1 and ATF-2.

Authors:  Jose Sangerman; Moo Seung Lee; Xiao Yao; Eugene Oteng; Cheng-Hui Hsiao; Wei Li; Sima Zein; Solomon F Ofori-Acquah; Betty S Pace
Journal:  Blood       Date:  2006-08-08       Impact factor: 22.113

6.  Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells.

Authors:  Vladan P Cokic; Silvana A Andric; Stanko S Stojilkovic; Constance T Noguchi; Alan N Schechter
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

7.  Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.

Authors:  Jane A Little; Kristine Partovi Hauser; Sabrina E Martyr; Amy Harris; Irina Maric; Claudia R Morris; Jung H Suh; James Taylor; Oswaldo Castro; Roberto Machado; Gregory Kato; Mark T Gladwin
Journal:  Eur J Haematol       Date:  2008-02-10       Impact factor: 2.997

8.  Short-chain fatty acid-mediated effects on erythropoiesis in primary definitive erythroid cells.

Authors:  Himanshu Bhatia; Jennifer L Hallock; Amrita Dutta; Shay Karkashon; Lauren S Sterner; Toru Miyazaki; Ann Dean; Jane A Little
Journal:  Blood       Date:  2009-04-20       Impact factor: 22.113

9.  Molecular mechanisms underlying synergistic adhesion of sickle red blood cells by hypoxia and low nitric oxide bioavailability.

Authors:  Diana R Gutsaeva; Pedro Montero-Huerta; James B Parkerson; Shobha D Yerigenahally; Tohru Ikuta; C Alvin Head
Journal:  Blood       Date:  2014-01-15       Impact factor: 22.113

10.  Immunoblotting conditions for human hemoglobin chains.

Authors:  Yusuke Suzuki; Yoshihiko Takeda; Tohru Ikuta
Journal:  Anal Biochem       Date:  2008-04-09       Impact factor: 3.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.